Navigation Links
Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer

BERKELEY, Calif., Feb. 9 /PRNewswire/ -- Aerovance Inc. today announced the appointment of Babatunde A. Otulana, M.D., to the position of senior vice president and chief medical officer.

Dr. Otulana, 52, will provide medical as well as organizational and regulatory leadership to the company as it moves forward with the development of AerovantTM for uncontrolled asthma and AerodermTM for severe atopic eczema. He has more than 20 years of experience in pulmonary research and product development.

"Tunde has a wealth of experience in the planning and implementation of clinical development programs for pulmonary drugs," said Mark Perry, Aerovance's president and chief executive officer. "He will focus on advancing Aerovant through clinical development, beginning with our upcoming Phase IIb clinical trial in patients living with uncontrolled asthma, while further developing Aerovance's pipeline."

Prior to joining the company, Dr. Otulana worked with Aradigm Corp., where he most recently served as senior vice president, development, and chief medical officer. At Aradigm, his responsibilities included the management of all clinical development, regulatory affairs, QA & QC, and R&D activities for respiratory specialty pharmaceutical products. Prior to Aradigm, he was a medical reviewer and team leader at the Division of Pulmonary Drug Products Center for the Drug Evaluation & Research of the U.S. Food and Drug Administration (FDA). Dr. Otulana is a practicing pulmonologist and has published numerous articles in peer-reviewed journals, most recently in the field of pulmonary delivery of therapeutics.

"I am excited to be joining the Aerovance team as the company advances its unique pipeline to meet significant unmet medical needs in the field of allergy and pulmonary medicine," said Dr. Otulana. "Aerovant and Aeroderm represent a new class of compounds which, if successful in development, will provide new tools for physicians in the management of intractable severe asthma and atopic dermatitis respectively, in millions of patients."

Aerovant is a recombinant human IL-4 variant that is a potent inhibitor of IL-4R alpha, a shared component of both the IL-4 and IL-13 receptors. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004.

Aerovance Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. For more information, visit

Editor's Note: Photograph available on request

    Contact:    Andreas Marathovouniotis or David Schull
    Russo Partners
                212-845-4235 or 212-845-4271

                Dave Happel
                Aerovance Inc.

SOURCE Aerovance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aerovance Secures $20 Million in Debt Financing
2. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
3. January 2009 - Rahu Appoints David Greensmith to Non Executive Directo
4. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
5. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
6. Qforma Appoints Two New Executives
7. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
8. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
9. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
10. Cumberland Pharmaceuticals Appoints Lee Product Director
11. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
Post Your Comments:
(Date:11/23/2015)... Calif., Nov. 23, 2015   Ceres, Inc . ... today financial results for the fiscal year ended August ... --> --> During ... forage and feed products with a better balance of ... signed distribution agreements with several leading crop input providers ...
(Date:11/23/2015)... ... November 23, 2015 , ... Shimadzu ... of its Nexera UC Unified Chromatography system. The award from R&D magazine recognizes ... products of the year in the analytical and testing category. R&D Magazine chose ...
(Date:11/23/2015)... 2015 The royalty-free a ... to develop daclatasvir for 112 low- and m ... --> --> The Medicines Patent Pool ... medicine, signing an agreement with Bristol-Myers Squibb for daclatasvir, a ... genotypes of the HCV virus.  The royalty-free licence will enable ...
(Date:11/23/2015)... 23, 2015 biochar market ... 2015, and it is expected to grow with a ... driving the growth of the global market include improved ... of biochar, increased government initiatives and stringent environmental regulations, ... stringent environment regulations are the key drivers for the ...
Breaking Biology Technology:
(Date:11/19/2015)... MOUNTAIN VIEW, Calif. , Nov. 19, 2015 /PRNewswire/ ... authentication market, Frost & Sullivan recognizes BIO-key with the ... Strategy Leadership. Each year, Frost & Sullivan presents this ... comprehensive product line catering to the needs of the ... which the product line meets and expands on customer ...
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
Breaking Biology News(10 mins):